Feasibility Study on Listing of Pharmaceutical Enterprises Based on Financial Analysis: Take Company Y as an Example

Abstract

Health has always been one of people’s demands for a high quality of life. For thousands of years, both Chinese and Western medicine have accumulated a lot of medical knowledge and ideas. However, due to the weakness of China in the past century, Chinese medicine has become irrelevant. However, with the outbreak and persistence of COVID-19 and China’s actions in the fight against the epidemic, people have further realized the importance of health, and TCM has again entered people’s field of vision. Taking Company Y as an example, this paper analyzes the listing feasibility of Company Y from its macro environment, basic overview, advantages and disadvantages in the industry, financial indicators, enterprise valuation and other aspects. Then, based on the above analysis and combined with the development trend and recent development goals of the enterprise, it concludes that under the current macro and micro environment, Company Y can and should be encouraged to list on the New Third Board, with a stock price of about 7 yuan and a price-earnings ratio of about 25 times.